麻豆视频

Middle East And Africa DPP-4 Market Trends and Insights

The Tradjenta segment is expected to witness the highest CAGR in the Middle East and Africa Dipeptide Peptidase 4 (DDP-4) Inhibitors Market over the forecast period

The Tradjenta segment is expected to register the highest CAGR of about 7.6% in the Middle East and Africa dipeptide peptidase 4 (DDP-4) inhibitors market over the forecast period.

Tradjenta is a prescription drug that helps improve blood glucose control in adults with type-2 diabetes and is considered an adjunct treatment to diet and exercise. It is also used as an add-on therapy to insulin. Tradjenta should not be used in patients with type-1 diabetes or for the treatment of diabetic ketoacidosis. The persistence of oral antidiabetic treatment for type-2 diabetes is characterized by drug class, patient characteristics, and severity of renal impairment. Unlike older classes of glucose-lowering drugs such as sulfonylureas and insulin, DPP-4 inhibitors have an inherently low risk of causing hypoglycemia due to their glucose-dependent insulinotropic mechanism of action mediated via the incretin hormone glucagon-like peptide-1.

麻豆视频 73 million adults were living with diabetes in 2021 which is estimated to increase to 95 million by 2030 in the IDF MENA Region. Governments in the ME have identified the threat of diabetes and started to respond with various policies, initiatives, and programs. Six out of 15 countries in this region still do not have a national operational action policy for diabetes. Many countries still do not have a national strategy to reduce overweight, obesity, and physical inactivity, which are important risk factors for diabetes. Most counties have fully implemented national diabetes treatment guidelines. However, constant measures are being taken to minimize diabetic complications.

Owing to the rising rate of obesity, the growing genetic factors for type-2 diabetes, the increasing prevalence, and the aforementioned factors, the market is likely to grow.

Saudi Arabia holds the highest market share in the Middle East and African DPP-4 Market in the current year

Saudi Arabia holds the highest market share in the Middle East and Africa DPP-4 market in the current year and is expected to register a CAGR of around 3.1% over the forecast period.

More than one in ten people in Saudi Arabia were living with diabetes, and the prevalence of the disease was expected to almost double by 2045, according to the IDF 2021 report. The IDF report also mentioned that 4.27 million people in Saudi Arabia, which has a population of about 34.8 million, have diabetes, while 1.86 million people have the disease but are yet to be diagnosed.

The growing incidence, prevalence, and progressive nature of the disease have encouraged the development of new drugs to provide additional treatment options for diabetic patients. Non-insulin treatments, used as first-line therapies for patients suffering from type 2 diabetes, currently capture more than half the sales in the anti-diabetic market. Over the past decade, two important classes have entered this market: dipeptidyl peptidase-4 inhibitors (DPP-4) and sodium-glucose cotransporter-2 inhibitors (SGLT-2). Oral antidiabetic agents work in various ways to reduce blood sugar levels in people with type-2 diabetes; some stimulate insulin secretion by the pancreas, and others improve the responsiveness of cells to insulin or prevent glucose production by the liver. Others slow the absorption of glucose after meals.

The Saudi Government declared that the country has a growing demand for quality healthcare services, spurred by changes including an increasing and aging population and a growing prevalence of lifestyle diseases such as diabetes and obesity in July 2022. The government and private sector are both involved in working on healthcare entities, certifications, and regulations. The government is taking steps to have 100 percent of Saudi citizens covered by insurance and is working towards ensuring affordability, access, and quality digital healthcare and primary care with cost-effectiveness.

Owing to the aforementioned factors, the market is expected to grow during the forecast period.

Market Opportunities and Future Outlook

With the Middle East and Africa DPP-4 inhibitors market at USD 813.51 million in 2026, a key opportunity sits in improving product availability and continuity of supply across fragmented tender and retail channels, supported by new regional manufacturing and logistics investments. In February 2026, STADA signed to invest over EUR 85 million in a Sudair City (Saudi Arabia) manufacturing facility designed for 300 million units per year, including type 2 diabetes treatments, aligning with Saudi localization goals and offering a pathway to more resilient in-region supply for chronic therapies.

A second whitespace area is faster market access and broader geographic reach through GCC-focused distribution and lifecycle management, as supply-chain and registration execution increasingly differentiate portfolios that are otherwise mature. In May 2026, Novo Nordisk opened a global distribution centre in the UAE intended to serve 70 countries across the Gulf, Africa, and Central Asia, and in June 2026 it signed an MoU with the Emirates Drug Establishment (EDE) to enhance pharmaceutical manufacturing and supply-chain security. These actions highlight active investment toward regional hubs and local capability building that can support more consistent launches, better stock availability, and stronger tender participation across MEA diabetes care pathways.